March 2026
Analysis of more than 65,000 active clinical trials by clinical data science company Phesi has found that 4,361 studies are impacted by the current Middle East disruption, with Phase III oncology trials most exposed:
A new study at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, has found that metformin, a widely prescribed diabetes drug, could help counter the metabolic strain of hormone therapy, when fatigue and other side effects often limit physical activity:
Infrastructure and real estate investor Aviva Capital Partners, and Socius, a mixed-use developer, have unveiled plans for a new £1bn project to create a globally leading centre for cancer research and treatment in Sutton, London, alongside the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust:
Swiss pharmaceutical research company Idorsia has reported positive top-line data from its Phase II dose-finding trial evaluating daridorexant, a dual orexin receptor antagonist, for paediatric insomnia disorder:
A new study co-led by the University of Glasgow and published in the Journal of the American College of Cardiology reveals that African countries remain severely underrepresented in randomised controlled trials (RCTs) published in the world’s leading medical and cardiovascular journals:
Danish pharmaceutical company ALK-Abelló A/S has announced that the European Commission has granted marketing authorisation for Eurneffy 1 mg for children aged 4 and older living with severe allergies. The therapy is the first and only needle-free adrenaline treatment for anaphylaxis. It will be available across all 27 European Union (EU) member states, plus Iceland, Norway and Liechtenstein:
In a new position statement the British Pharmacological Society has announced the need for a fundamental shift in clinical trial design to include pregnant and breastfeeding women, to make up for the “significant evidence gap” surrounding medication use in these groups:
Kyowa Kirin has announced the global discontinuation of all ongoing clinical trials for rocatinlimab, an anti-OX40 monoclonal antibody under investigation for moderate-to-severe atopic dermatitis (AD), prurigo nodularis, and moderate-to-severe asthma:
AstraZeneca has announced its experimental antibody drug tozorakimab met its main goal in two Phase 3 trials in chronic obstructive pulmonary disease, helping reduce flare-ups in a broad range of people with the condition:
The Dementia Trials Accelerator led by Health Data Research UK and the UK Dementia Research Institute has taken a significant step towards transforming dementia clinical trials in the UK by welcoming its first participants into clinics for simple tests that will ultimately recruit the right people into clinical trials quicker:
AI-powered robotic tools are muscling in on tasks typically done by humans in the so-called ‘self-driving’ laboratory revolution. What does the future hold?:
February 2026
A pressing concern in U.S. biomedical research is that early clinical development is moving overseas, particularly to China and Australia:
dcri.org/stories/early-phase-trials-move-overseas-experts-urge-us-act and www.cnbc.com/2026/02/18/fda-chief-warns-us-is-losing-ground-to-china-in-early-drug-trials.html
Around 27,000 new clinical trials were registered in India from January 2024 to June 2025, up by 50% from 2023, meaning it hosted 23% of all clinical trials worldwide. That ranks it second in the list of most popular trial destinations, behind China and ahead of the US:
ctri.nic.in/Clinicaltrials/login.php
Advances in organ and computer models are raising the prospect that some animal experiments could be eliminated. But there are still huge hurdles to overcome:
A phase 1 trial has begun at City of Hope National Medical Center in California into whether the twenty-year old Mirasol process can be used to fight ovarian cancer by inactivating tumour cells and then reintroducing them into the body to try to set off a helpful immune response:
iiDiagnostics, a company formed by iiCON, and Canadian biotech Eyam Health, are collaborating to bring forward Eyam Health’s novel SARS-CoV-2 vaccine candidate using advanced automated organoid models in a pioneering UK/Canada collaboration. The project will be the first commercial project to be carried out in the state-of-the-art Liverpool Robotic Infection Research Laboratory:
Researchers have identified a promising new speech biomarker that could significantly enrich clinical trials by reducing sample size requirements and enhancing statistical outcomes for clinical trial participants with schizophrenia:
Why clinical trials are inefficient, why it matters and what we can do about it:
learninghealthadam.substack.com/p/why-clinical-trials-are-inefficient
Patients will be able to access clinical trials through the NHS app, as part of the UK government’s new National Cancer Plan and the Rare Cancers Bill which is currently going through Parliament. It is hoped that this will give patients with rare cancers, including brain cancers, a better chance of survival:
New data from CGT Catapult's UK 2025 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database shows continued growth in advanced therapy clinical trials in the UK for 2025. The number of ongoing advanced therapy clinical trials reached 193 in 2025, with 56% being early-stage trials and 80% being commercially sponsored:
There have been no new types of antibiotic in over 40 years.
www.youtube.com/watch?v=hItlmfXZBQU
The Science Awareness Project showcases a snapshot of today's scientific medical research:
www.scienceawarenessproject.org
Memantine, a long-approved and cost-effective drug used to treat Alzheimer’s disease, could also benefit patients with sickle cell anaemia, the world’s most common genetic disorder, in the future:
Following its previous refusal to review Moderna’s seasonal flu vaccine, mRNA-1010, the US Food and Drug Administration (FDA) has changed course – agreeing to assess the jab through a two-pronged approach:
www.pharmaceutical-technology.com
NEXT Life Sciences, a leader in reproductive and sexual health companies, is hoping to revolutionise the contraceptive category with two male birth control options, both in Phase II clinical trials:
January 2026
An overview of 2025, a turbulent year for the pharmaceutical industry:
New data from Cell and Gene Therapy (CGT) Catapult shows continued growth in advanced therapy clinical trials in the UK for 2025, with the number of early-stage trials remaining high. The number of ongoing advanced therapy clinical trials reached 193 in 2025, with 56% being early-stage trials and 80% being commercially sponsored:
The UK Home Office publishes detailed annual statistics on the use of animals in science, including procedures for acute and sub-toxicity testing methods such as LD50 (Lethal Dose 50) and LC50 (Lethal Concentration 50). According to the latest published figures for 2024, there were 11,992 procedures in this category; the statistics include a breakdown by species: https://www.theyworkforyou.com/wrans/?id=2025-12-03.96751.h&s=%28Chemicals+OR+CRO+OR+Pharmaceuticals%29#g96751.r0. In related news, the UK government is committed to non-animal alternatives in science and has published a strategy to support their development, validation and adoption:
www.gov.uk/government/publications
Two groundbreaking studies published in the Nature Medicine journal suggest faecal microbiota transplants (FMT) can dramatically improve cancer treatment. The first study shows that the toxic side effects of drugs to treat kidney cancer could be eliminated with FMT. The second study suggests FMT is effective in improving the response to immunotherapy in patients with lung cancer and melanoma:
India has made key amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019, in line with the directions of Prime Minister Narendra Modi. The amendments are aimed at simplifying regulatory processes, reducing approval timelines, and enabling faster conduct of clinical research and pharmaceutical development in the country:
At the 2025 American Society of Clinical Oncology annual meeting, researchers presented results of a large Phase 3 clinical trial that led to the approval of inavolisib which significantly improved survival rates among patients with hormone receptor-positive breast cancer who are resistant to standard endocrine therapy. A limitation of the study is that it enrolled only 0.6% Black patients, with more men enrolled than Black women – a moral failure and bad science:
The Functional Gut Clinic (FGC), a provider of specialist gastrointestinal diagnostics, has announced the launch of its dedicated GI Clinical Trials establishing the organisation as the UK’s first boutique, end to end clinical research provider focused exclusively on digestive health:
www.clinicalservicesjournal.com
New data from the UK medicines regulator, the MHRA, has shown an increase in clinical trial activity in the country, after years of decline, which it says shows that the promise of reforms following Lord O'Shaughnessy’s report is already starting to have an effect:
Vortex Biotech Holdings Limited has announced the opening of its advanced laboratory facilities at Manchester Science Park. The new site significantly enhances R&D and commercial delivery capacity and strengthens the company’s position as a leader in liquid biopsy technologies for precision oncology:
A major UK clinical trial has shown that adding the corticosteroid dexamethasone to standard antiviral treatment for encephalitis (brain inflammation), caused by herpes simplex virus (HSV) does not improve long-term outcomes overall. However, early use may lead to better recovery, and the treatment is safe for patients with suspected encephalitis:
www.clinicalservicesjournal.com
The UK’s Medical Research Council Centre of Research Excellence in Clinical Trial Innovation (MRC CoRE CTI), which is being set up in partnership with the National Institute for Health and Care Research, will receive £50 million over 14 years with the ambition of transforming the clinical trial landscape:
For the first time in a while, the biotechnology industry starts a new year with momentum, much of it fuelled by clinical trial results. BioPharma Dive selects ten to watch in the first half of this year:
The European Commission has released plans intended to accelerate clinical trial approvals across the EU and cut costs by as much as 80–90% through the use of AI-enabled trials. EU average clinical trials take well over 100 days; in the UK, it’s c. 60 days. The aim is to drive that down to 47–50 days on average:
Clinical development accelerator Quotient Sciences and CRO Lindus Health are joining forces to create a streamlined one-stop- shop process for clients to advance from first-in-human (FIH) up to pivotal trials:
In a free virtual panel, industry experts will discuss practical examples and considerations for applying AI in pharma’s clinical trials. Date: 26 March 2026, Time: 3 PM GMT:
Democrat Governor Maura Healey has written to U.S. Health and Human Services Secretary Robert F. Kennedy Jr. to demand that he restore funding cuts to the National Institutes of Health (NIH) that have stopped 380 clinical trials and impacted more than 74,000 patients nationally, including 18 clinical trials and 13,000 patients in Massachusetts:
A review of an inclusive recruitment strategy that was adopted during the ‘Live Well with Parkinson’s’ trial, funded by the NIHR’s Programme Grants for Applied Research Programme:
Two of the largest clinical trials of their kind have shown that a daily dose of oral semaglutide did not delay progression of the neurodegenerative disease Alzheimer’s:
Analysis commissioned by the Department of Science, Innovation and Technology (DSIT) has found positive outcomes for UK research projects backed by the Horizon R&D programme. UK researchers secured £6.8 billion in funding through nearly 11,000 projects via the Horizon 2020 programme (H2020) from 2014-2020, including for clinical trials:
The FDA has proposed cutting fees for early-stage companies conducting clinical development in the U.S. instead of abroad. The proposal is designed to incentivize U.S. drug development by tacking on higher fees for those not running phase 1 trials in the country:
